Anorectal melanoma – histopathological and immunohistochemical features and treatment  by Cruz, Geraldo Magela Gomes da et al.
OA
i
G
S
R
R
a
b
c
d
e
a
A
R
A
A
K
A
A
H
I
S
h
2
Ej coloproctol (rio j). 2014;34(2):95–103
Journal of
Coloproctology
www.jco l .org .br
riginal Article
norectal melanoma – histopathological and
mmunohistochemical features and treatment
eraldo Magela Gomes da Cruza,e, José de Souza Andrade Filhob,c, Gil Patrusb,
inara Mônica de Oliveira Leitea,c,∗, Ilson Geraldo da Silvaa,c,d,
icardo Guimarães Teixeiraa,c, Áurea Cassia Gualberto Bragaa,c,
enata Magali Ribeiro Silluzio Ferreiraa
Grupo de Coloproctologia, Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, MG, Brazil
Sociedade Brasileira de Patologia (SBP), São Paulo, SP, Brazil
Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, MG, Brazil
Service of Male Coloproctology, Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brazil
Service of Female Coloproctology, Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brazil
r t i c l e i n f o
rticle history:
eceived 27 October 2013
ccepted 4 February 2014
vailable online 13 April 2014
eywords:
norectal melanoma
norectal cancer
istopathology
mmunohistochemistry
urgical treatment
a b s t r a c t
Anorectal melanomas should be characterized by location (anal, rectal and anorectal), color,
size, shape and mobility and microscopically, by melanocyte subtypes, grade of melanin
pigmentation, junctional changes in the squamous epithelium, atypical mitotic index, cel-
lular atypia, inﬂammatory inﬁltrate, vascular and perineural invasion, sentinel lymph node,
and anorectal parietal penetration. Anorectal melanomas must be staged by American Joint
Committee on Cancer (AJCC) and/or TNM Classiﬁcation of Malignant Tumours (TNM) crite-
ria. As melanocytes can present with several shapes, sometimes the differential diagnosis
with other tumors in this region may be difﬁcult. Because of this, immunohistochemistry is
mandatory to attain a precise diagnosis. This study is a report of 14 patients with anorectal
melanoma, in whom histological examinations were remade and immunohistochemistry
wasperformedwith severalmarkers formelanocytes and for other tumor cells of the anorec-
tal region, properly establishing the diagnosis. The most rational surgery is the extended
local resection, when the disease is restricted to the area or the abdominoperineal resection
to advanced lesions. Regardless of the technique used, the results are always poor. The
authors deny any efﬁcacy of current radio and/or chemotherapy as part of treatment of
anorectal melanoma. Target-therapy for metastatic disease has been considered a good
strategy, but the results are still inconclusive.© 2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda.
 Study carried out at Coloproctology Group of Santa Casa de Belo Horizonte (GCP-SCBH), Post-Graduation and Research Program of
Santa Casa de Belo Horizonte (PPGP-SCBH) and Faculdade de Ciências Médicas de Minas Gerais (FCMMG).
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ttp://dx.doi.org/10.1016/j.jcol.2014.02.006
237-9363/© 2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda.
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Melanoma anorretal – diagnósticos histopatológico e imunohistoquímico
e tratamento
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r e s u m o
Os melanomas anorretais (ARM) devem ser caracterizados pela localizac¸ão (anal, retal
e anorretal), colorac¸ão, dimensão, forma e mobilidade. Microscopicamente, por tipos de
melanócitos, graduac¸ão da pigmentac¸ão melânica, alterac¸ões juncionais sob o epitélio
escamoso, índice mitótico atípico, atipias celulares e citoplasmáticas, inﬁltrado inﬂa-
matório, invasões vascular e perineural, linfonodo sentinela e penetrac¸ão parietal. Devem
ser estadiados pelos critérios American Joint Committee on Cancer (AJCC) e/ou TNM Classi-
ﬁcation ofMalignant Tumours (TNM). Comoas células doARMsão variáveis, isto torna difícil
o diagnóstico diferencial com outros tumores da região anorretal. Assim, faz-se necessária
a realizac¸ão de IHC. Apresentamos uma série de 14 pacientes, nos quais foram refeitos
exames histológicos e realizados IHCs com vários marcadores, ﬁrmando corretamente o
diagnóstico. Os trabalhos mostram que a cirurgia mais racional é a excisão local alargada
(ELA) em casos de doenc¸a localizada e ressecc¸ão abdominoperineal do reto (APR) para lesões
avanc¸adas. Independente da técnica, a sobrevida de cinco anos é inferior a 35%; a sobrevida
média não ultrapassa 26 meses; o tempo livre de doenc¸a é inferior a 10 meses; e a sobre-
vida global não ultrapassa é de 32 meses. Não há correlac¸ão entre melhora dos resultados
com qualquer tratamento adjuvante. As terapias-alvo para doenc¸a metastática comec¸am a
apresentar resultados animadores, ainda inconclusivos.
© 2014 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.
Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
The anorectal melanoma (ARM) is a tumor that originates in
melanocytes – cells that produce melanin – and which devel-
ops in the anal canal. The ﬁrst description of ARM in the
literature dates from 1897, byMoore.1 ARMs are rare. Themost
common sites of incidence of melanomas are the skin (91.2%),
followed by eyes (5.2%) and the anorectal region (less than
1%).2 ARMs occur more often between the sixth and eighth
decades of life3 and are more frequent in women.4 The etiol-
ogy of ARMs is associated to exposure of the skin to ultraviolet
rays, which explains its rarity in the anorectal region, usually
not exposed.5
The symptoms are common to other tumors of the anorec-
tal region: elimination of mucus and blood through the anal
canal, anal pain, feeling of rectal fullness or incomplete evac-
uation, externalization of tumor and changes in bowel habits.
The proctologic examination allows detection of the tumor,
but itmay bemisdiagnosed as other diseases of the anal canal:
thrombosed hemorrhoids or other tumor lesions, especially
if the lesion is not pigmented. Examination of the inguinal
regions should be performed to search for metastatic nodes.
A biopsy is mandatory to attain proper diagnosis.5
Histological (hematoxylin–eosin) examination character-
izes the lesion regarding cell type, degree of melanin
pigmentation and mitotic index. Melanocytes can be found in
four different forms: epithelioid, lymphoma-like, spindle-cell
and pleomorphic, which complicates the differential diag-
nosis of some diseases such as Paget, Bowen, lymphomas,
undifferentiated carcinomas, sarcomas and gastrointestinal
stromal tumor (GIST). Thus, especially in amelanic ARMs (butalso in melanocytic ones), immunohistochemistry should be
performed – the study of protein expressions of melanocytes.6
The possible surgical procedures are: local excision, which
may be extended, and abdominoperineal resection with or
without inguinal lymphadenectomy. Several authors advo-
cate extended local excision as the preferred procedure, as
the prognosis is poor and similar, regardless of the surgi-
cal approach (whether economic or radical).3,7,8 However, in
advanced cases, or as rescue surgery after extended exci-
sion and recurrence, abdominoperineal resection can be
performed.9
Adjunctive treatments show that low efﬁcacy and
melanomas are radio-resistant. Thus, radiation therapy is
indicated only in special cases, as a palliative measure. Sev-
eral chemotherapeutic agents have been tried without any
substantiated conclusions about their beneﬁt.10 The possi-
bility of studying speciﬁc mutations in ARMs has shown
that melanomas are heterogeneous regarding their tumor
biology.11 Target molecules can be identiﬁed in some sub-
groups, allowingmore speciﬁc treatmentwith better response.
One of these subgroups includes patients with mutations in
the BRAFV600E gene. BRAF inhibitors induce tumor regression
in up to 70% of patients with metastatic disease.12
Another subgroup includes patients with melanomas with
KIT gene aberrations, who can beneﬁt from c-KIT blockers:
imatinib, dasatinib, sunitinib and sorafenib. There are several
ongoing phase II case reports, with promising results.13
This study reports 14 cases of melanoma diagnosed and
treated at the Coloproctology Unit of Santa Casa de Belo Hori-
zonte, during a 30-year period (1982–2012). The objectives are
to report cases and demonstrate that immunohistochemistry
is the gold-standard diagnostic method (Fig. 1).
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Fig. 1 – Illustrations of the 14 patients with ARMs: four surgical specimens of abdominoperineal resection (patients A, B, C
and D), ﬁve patients submitted to local resection (patients E*, F, G, I, L), one with protective stoma (patient E*), one to
extended local resection (patient H), one to relief colostomy (patient K), two to hemorrhoidectomy with the incidental
ﬁnding of melanoma (patients M and N), and one who did not undergo surgery (patient J).
M
T
w
tethodshis is a historical series, given the rarity of the lesion,
here the organization and method of the main investiga-
or were essential for the completion of the work. It wasonly possible to carry it out because the necessary mate-
rial was stored and cataloged, allowing new tests to be
performed.Review of medical records and histopathological and
immunohistochemistry studies were performed in slides and
parafﬁn blocks of tumors. Age, gender, ASA classiﬁcation
98 j coloproctol (rio j). 2014;34(2):95–103
Table 1 – Main IHC markers used in the diagnosis of ARM and several other anorectal diseases, making the differential
diagnosis between them.
ARM Paget Bowen Lymphoma UCA GIST LMS
ARM markers
S-100 protein S
HBM-45 S
Melan-A/MART-1 S
Vimetime S S
C117 (c-kit) S/N S/N S
PDGFRA S S
TU markers no ARM
CEA S
CK high MW (34BE12, AE1) S
CK low MW (35BE12, AE2, AE3) S
CD34 (QBEN-10) S
CD45 (PTPRC) S
CD68
Chromogranin A (CHGA) S
Synaptophysin (SYP) S
Desmin (DES) S S
Caldesmon (CALD-1) S
DOG-1 S
ma; T
cachectic.
Eight patients had goodoverall health status, threehad reg-GIST, Gastrointestinal Stromal Tumor; UCA, undifferentiated carcino
of patients, type of surgery, TNM classiﬁcation and sur-
vival/mortality data were collected from the sample.
The patients were submitted to the four basic types of
surgery: local resection, extended local resection, colostomy
derivation (alone or associated with local resection) or
abdominoperineal resection of the rectum (APR).
Histopathological analysis was performed with H&E stain-
ing (hematoxylin–eosin) in 5-mm slides. Cell type (epithelioid,
spindle cell, lymphoma-like and pleomorphic); degree of
melanin pigmentation (severe, moderate and focal, or
absent); junctional activity under the squamous epithelium;
melanocytic involvement of the anorectal junction; presence
of abundant and eosinophilic cytoplasm; type of nuclei (round
and vesicular); prominent eosinophilic nucleoli; presence of
inﬂammatory inﬁltrate; perineural and vascular invasion;
parietal invasion and mitotic index per microscopic ﬁeld were
characterized. New slides were made from the parafﬁn blocks
of eight patients. In the remaining patients, the slides were
reviewed (four) or only considered (two). All analyses were
performed by the same pathologist.
Immunohistochemistry (IHC) was performed in 12
patients. In four cases IHC was performed only for ARM
markers. In eight cases IHC was performed for ARM markers
and other non-ARM anorectal tumors. The immunohisto-
chemical study was not possible in only two patients. All
examinations were performed by the same pathologist.
Immunohistochemistry allows conﬁrmation of melanoma
and the differential diagnosis with other anorectal tumors.
Table 1 shows the major markers studied.
All the materials used (clinical records, histopathology
and immunohistochemistry reports, slides-12 patients and
parafﬁn-9 patients); the free and informed consent forms
signed by the four patients still alive and approval by the
Research Ethics Committee of Santa Casa de Belo HorizonteU, Tumor.
approving the project are in the possession of the main inves-
tigator.
Results
Table 2 shows the sample descriptive data: age, gender, ASA
classiﬁcation of patients, type of surgery, TNM classiﬁcation
and survival/mortality. Age ranged from 44 to 81, with a mean
age of 64.7 years. Therewerenine (64.3%) females andonly two
melanodermic patients (14.2%). The time of anorectal symp-
toms varied between three and 12months (85.7%)with amean
of 7.7 months. Only eight patients (57.1%) perceived the pres-
ence of an anal tumor, but 92.2% complained of bleeding in
stools and/or clothing. Most patients complained of symp-
toms during evacuation (92.9%): anal pain (57.1%), sensation
of incomplete evacuation (14.2%), tumor prolapse during evac-
uation (21.4%). Fecal incontinence occurred in four (28.6%).
Six (42.8%) had clinical symptoms of anemia and ﬁve patients
(35.7%) had overall poor health status.
Comorbidities
According to the ASA – American Society of Anesthesiology –
classiﬁcation, six patients were ASA I, three were ASA II and
ﬁvewereASA III. The comorbiditieswerehypertension in eight
patients, diabetes mellitus in three, congestive heart failure in
two, chronic obstructive pulmonary disease in one, lower-limb
varicose disease in two, anemia in four and two patients wereular and three patients had poor health status, one of them
with synchronous breast cancer.
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Table 2 – Sample characteristics – patients numbered from 1 to 14.
Number Age Gender ASA Surgery TNM Survival/mortality
1 66 M III APR T3N1M0 Death <1 month
2 66 F I APR T3M0N0 Death 36 months
3 71 F II APR T3N1M1 Death 8 months
4 62 M I APR T3N1M1 Death 14 months
5 56 M I LR T3N1M1 Death 5 months
6 46 M II LR T3N0M0 Death 12 months
7 44 F I ELR T1N0M0 DFS 7 years
8 52 F I ELR T1N1M1 Death 7 months
9 66 M III ELR T1N0M0 DFS 2 years
10 81 F III NO T3N1M1 Death 1 months
11 72 F III S T4N0M0 Death 8 months
12 71 F III ELR T1N0M0 DFS 14 years
13 62 F I HEM T1N0M0 DFS 17 years
14 72 F II HEM T1N0M0 DFS 12 years
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4M, male; F, female; ASA, American Society of Anesthesiology, classiﬁc
local resection; NO, not operated; S, palliative stoma; HEM, hemorrho
roctologic examination and colonoscopy
he tumor was visible on inspection in eight (57.1%) patients.
n 11 patients the tumor was palpable and the pectineal line
as affected by the tumor in 13 (92.9%) cases. In 10 patients the
umor was anorectal, in three cases it was located in hemor-
hoidal papilla and in one case the tumor was entirely rectal.
he mean size was 3.7 cm. Nine tumors were dark, one was
ight in color (amelanic) and two had dark and light mixed
reas. In nine patients (64.3%) the tumor was ﬁxed and in
ve mobile, of which one was pediculated and two found
n hemorrhoidal disease. In these two patients the diagnosis
asmade after histological analysis of thehemorrhoidectomy
pecimen. The tumors were ulcerated in one case, vegetating
n 10 cases and ﬂat in one case, in addition to the two located
n hemorrhoids.
taging
ith the exception of the two patients whose diagnosis was
ttained in hemorrhoidectomy specimens, all others under-
ent staging according to the tests available at the time of
iagnosis. Imaging studies were most often performed.
RM staging characteristics
. Tumor location: in 10 cases (71.4%) the tumor was anorec-
tal; in three cases (21.4%) it was located in hemorrhoidal
papilla, of which two were casual ﬁndings during hemor-
rhoidectomy, and in one case (7.1%) the tumor was rectal.
. Anorectal wall thickening: present in ﬁve patients (35.7%),
absent in seven (50.0%) and HD in two cases (14.2%).
. Lymph nodes: para-iliac lymph nodes were observed in six
patients (42.9%); inguinal chain lymph node in ﬁve patients
(35.7%); paravertebral chain lymph nodes in four patients
(28.6%), concomitantly. Invasion of the vagina and bladder
was observed in one patient (7.1%).
. Metastases: liver metastases were diagnosed in ﬁve
patients (35.7%); lung metastases in four (28.6%), no bone
metastases; subcutaneous metastases spread throughout; APR, abdominoperineal resection; LR, local resection; ELR, extended
omy; TNM, tumor staging system; DFS, disease-free survival.
the body in two (14.2%). At the second visit, due to disease
recurrence, pelvic-perineal recurrences, bone metastases
and overall metastases occurred.
Surgeries performed, chemotherapy and radiotherapy,
staging (TNM) of tumors, survival, disease-free interval
and mortality
1. Surgeries performed: four patients underwent APR (28.6%),
three underwent ELR with curative intent (21.4%), three
underwent LR without curative intent (21.4%), two did
not have the tumors resected (14.2%), and two underwent
surgery for HD with HP examination showing ARM post-
operatively (14.2%). Two were reoperated due to recurrent
disease (14.2%).Onewasoperatedafter theﬁrst surgery and
underwent left lobe hepatectomy for single metastasis in
the left lobe of the liver (7.1%).
2. Staging (TNM classiﬁcation): S (stage)-I (To-T2, No/Nx, Mo),
three patients; S-II (T3-T5, No/Nx, Mo), two patients; S-III
(To-T5, N1, Mo), one patient; and S-IV (To-T5, No/Nx, M1),
six patients.
3. Chemotherapy/radiotherapy: only one patient received CT
and none received RT.
4. Survival, disease-free interval and mortality: of the 14
patients, nine died (64.3%) and ﬁve remain alive and
disease-free (35.7%). For the nine patients who died, sur-
vival ranged from one to 36 months, with a mean survival
of 8.4 months. Disease-free survival ranged from 2 to 17
years in the 5 patients who are still alive (Table 2).
Histopathological analysis
1. Cell subgroups: pleomorphic cells were identiﬁed in two
cases; all the remaining 12 patients (85.7%) had epithelioid
cells concomitantly with spindle cells and “lymphoma-
like” cells were not observed in any cases.2. Melanin hyperpigmentation: 10 patients (71.4%) showed
diffuse and intense melanin hyperpigmentation; one
patient had no pigmentation; and three patients had pig-
mented and non-pigmented areas.
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Table 3 – IHC test results of 14 cases of ARM.
Immunohistochemistry analysis (IHC)
Antigens associated to the melanoma Partial antigens Antigens not associated to the
melanoma–associated to other anorectal tumors
S-100 HMB-45 MART-1 Vimetina (V9) c-kit CEA AE-1 AE-2 ACT DES h-CAL SYN QBEN-10 CD10
NEP
CD45
PTPRC
1 PD PD PD PD PF N N N N N N N N – N
2 PD PD PD P/N N N – – – – – – – – –
3 PD PD PD – –N N N N – – – – – – –
4 PD PF PD PD N N N N N N N N N – –
5 PD PD PD PD N N N N – – – – – – –
6 – – – – – – – – – – – – – –
7 PD PD PD PD N N N N – – – – – – –
8 – – – – – – – – – – – – – –
9 PD PD PD – N N N N – – – – – N –
10 PD PD PD – PF N N N – – – – – N –
11 – – – – – – – – – – – – – –
12 PD PD PD PD PF N N N – – – N – – N
13 – – – – – – – – – – – – – –
14 – – – – – – – – – – – – –PD, Positive/Diffuse; PF, Positive/Focal; N, Negative; –, not performed.
3. Junctional activity under the squamous epithelium: it was
not found in one case and it was not reported in ﬁve cases;
in the remaining eight patients, junctional activity under
the squamous epithelium was described (57.1%).
4. Elevated and Atypical Mitotic Index: except for one patient,
all the other 13 patients had elevated and atypical mitotic
index described (92.9%).
5. Perineural and Vascular Invasion: it was not found in three
patients, not reported in three patients and it was found in
eight patients, being only perineural in one patient, vascu-
lar in two patients and perineural and vascular in the other
ﬁve patients.
6. Parietal Invasion: could not be studied in ﬁve patients
(three unresectable tumors and two inoperable ones). In
the remaining nine patients: tumor invasion beyond the
musculature in four patients; mucosal invasion only in two
patients, up to the lamina propria in two and up to the
submucosa even in one case.
7. Chain lymph nodes: studied in four cases in which radi-
cal surgery was performed. Fourteen ganglia were found in
two, all without metastases, and two had 18 ganglia, three
with malignancy and 14 ganglia, 12 with metastases.
8. Other lymph nodes: ganglia found by imaging tests could
not be studied.
Immunohistochemical ﬁndings
Immunohistochemical (IHC) analyses were not performed in
ﬁve of the 14 patients: in the ﬁrst three because they were very
old patients and IHC was not available, and in the last two due
to the scarcity of material (hemorrhoidectomy). IHC analysis
was performed in all other nine patients with S-100 protein
and melanoma-associated antigens (HMB45 and Melan-A or
MART-1). Vimentin (V9) was tested in six patients. The c-kit,
CEA and cytokeratins (AE-1 and AE-2) were tested in the nine
patients studiedwith S-100 protein andmelanoma-associatedantigens. Actin, desmin, caldesmon-h and CD34 or QBEN-10
were tested in two patients; synaptophysin in three patients,
CD10 or NEP was tested in two patients, and CD45 or PTPRC
was tested in two patients (Table 3).
The tumor cells stained by markers and counterstained
with Giemsa, showed strong positivity for Vimentin – V9
(100%) and for melanoma-associated antigens – S-100 protein
(100%), HMB45 (100%) and MART-1 or Melan-A (100%). The c-
kit showed focal positivity in three cases (33%), and CD-68 and
Iron were positive in one case in which they were tested. They
showednegativity for highmolecularweight cytokeratins (AE1
and 34BE12); they were negative for low molecular weight
cytokeratin (35BE12 andAE2); negativity for CEA, smoothmus-
cle actin, Desmin, h-caldesmon, synaptophysin, CD34 (QBEN
-10), CD-10 (NEP) andCD45 (PTPRC) in cases inwhich theywere
tested (Table 3 and Fig. 2).
Discussion
Anorectal melanomas (ARMs) are rare tumors. In a review
of cancer cases in nine states, until 1993, Weinstock4 found
an incidence of 1.7 ARM cases per million inhabitants. In
other studies, the incidence ranged from 1 to 2% per million
inhabitants.14,15
In this study we cannot assess the real impact of ARMs. Of
the series of 14 cases, six were treated by the main investiga-
tor, within a universe of 40,000 anorectal examinations (0.15%
incidence) and among 973 cases of colorectal cancers (0.6% of
them).
The highest incidence of ARM is between the sixth and
eighth decades of life.3 In a reviewof 126 cases of ARMs treated
from 1973 to 2001, Podnosy et al. reported a higher prevalence
16 4in women (61%), with a mean age of 69.2 years. Weinstock
reported that the incidence was higher in women (between 54
and 76%) and higher in whites than in blacks. In this study we
also found a mean age of 64.7 years and a higher prevalence
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Fig. 2 – IHC of the ARM of patient I (9) (counterstaining with Giemsa). (A) S-100 protein: positive result (enucleate
cytoplasmic staining, with evident brownish color), (B) Melan-A: positive result (brownish cytoplasmic staining), (C) HMB-45
positive result (brownish cytoplasmic staining with granular pattern, corresponding to melanosomes), (D) CK-AE1/AE3:
negative result (the melanin pigment, originally brownish, acquires a greenish hue); (E) CD10: negative result (no brownish
s ing)
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hite.
Slingluff, Collmer and Seigler, in a review of 24 ARM cases,
dentiﬁed rectal bleeding as the most common symptom, fol-
owed by anal pain, visible or palpable mass, pruritus ani,
enesmus, prolapse and change in bowel habits.17 The symp-
oms of patients in this series coincide with this report,
n addition to overall poor health status in ﬁve patients
35.7%).
Proctologic examination in this series showed that the
umor was visible (57.1%) or palpable (92.9%) in almost all
ases. The mean size was 3.7 cm and in 12 patients the
umor was dark in color. These data show that the diagno-
is is easily suspected, although almost always delayed. In
3 patients the pectineal line was affected, which is consis-
ent with the literature.18 Tumor staging showed stage I in
1.4% of patients (two incidentalomas found during hem-
rrhoidectomy) and stage IV (42.9%) in most symptomatic
atients. Lymph node metastasis was found in six patients
nd distant metastases in ﬁve (liver, lung and disseminated
ubcutaneous). These ﬁndings are variable in the literature,3,18
ut corroborate the fact that the disease is severe at the
iagnosis.
Chute et al.6 evaluated 17 cases of primary ARM with
pecial reference to histopathology and IHC. The morpho-
ogical characteristics evaluated microscopically included cell
orphology, melanin pigmentation, junctional change and
itotic rate. Morphological subtypes of ARM were: epithe-
ioid (12 cases), spindle-cell (seven cases), lymphoma-like (10
ases) and pleomorphic (six cases). Melanin pigmentationwas
resent in nine cases; junctional change was present in six
ases and mitotic rate was three or more per high-frequency
icroscopy ﬁeld in eight cases..
These ﬁndings coincide with those of this series: as cell
subgroups, in 12 patients (85.7%) the ARMs had epithelioid
cells concomitantly with spindle cells; 10 patients (71.4%)
had diffuse and intense melanin hyperpigmentation; junc-
tional activity under the squamous epithelium was present
in eight patients (57.1%) and the high and atypical mitotic
index occurred in 13 of the 14 patients (92.9%). However, there
is no correlation between the morphological characteristics
described and prediction of survival.
As the differential diagnosis between amelanic ARM with
epithelioid cells and other anorectal diseases (Paget’s disease,
lymphoma, undifferentiated carcinoma and GIST) can be dif-
ﬁcult when considering only the histopathological criteria,
IHC has become a very important resource to establish the
correct differential diagnosis. Thus, after this test became
available (after 1985), almost all studies mention perform-
ing IHC for the diagnosis of ARM and differential diagnosis
with other diseases. Almost all test the ARM panel of mark-
ers (S-100 protein, Vimentin, Melan-A, HMB-45) and include
speciﬁc markers such as cytokeratins (Paget’s disease), CD45
(lymphoma), chromogranin and synaptophysin (undifferen-
tiated carcinoma), CD34 (GIST) and Desmin and caldesmon
(sarcoma).19
In this series there was a strong positivity for Vimentin
(100%), S-100 protein (100%), HMB45 (100%) and MART-1 or
Melan-A (100%), consistent with the literature.19 c-Kit showed
focal positivity in 33% and CD-68 and iron showed focal pos-
itivity in the only case in which they were tested. As for
the markers tested for differential diagnosis, they were all
negative (cytokeratins, CEA, smooth muscle actin, Desmin,
h-caldesmon, synaptophysin, CD34, CD10 and CD45).
None of these markers were predictive of survival.6 How-
ever, Ben-Izhak et al. described two markers – Ki67 and PCNA
j). 20
r
1
Surg Oncol. 1995;58:118.102 j coloproctol (rio
(Proliferating Cell Nuclear Antigen), which were associated
with advantage in survival – patients with high Ki67 and low
PCNA scores. These data have not been validated by subse-
quent studies.20
As for surgery, there is a consensus that the disease is
severe, with poor results and there is no difference in survival
of patients undergoing local excision or extended surgery,
such as abdominoperineal resection of the rectum. Consid-
ering the risks of major surgery and the inconvenience of a
deﬁnitive stoma, with signiﬁcant impact on quality of life, the
choice of most authors is the extended local excision, reserv-
ing APR for advanced cases or rescue in case of recurrence
after local resection.9,21–23
Four of the 14 patients in this series underwent APR due
to invasive ARMs, as ELR was not feasible. Three patients
underwent ELR with curative intent (21.4%), as they had local-
ized ARMs. Three patients underwent ELR without curative
intent (21.4%), as APR was not possible due to patient over-
all status. Two patients did not have their tumors resected
(14.2%), as they were not ﬁt to undergo the surgical procedure
and were considered inoperable. And two patients underwent
surgery for hemorrhoidal disease, with the histopathologi-
cal analysis disclosing the presence of ARM postoperatively
(14.2%).
Of the 14 patients studied, nine died and ﬁve remain alive
and disease-free. The mean survival time was 8.4 months. In
the literature, the overall survival varies among authors, but
there is consensus that it depends on the surgical technique
used (extended local resection or APR).9,22–23
Only one case series mentions the incidental ﬁnding
of ARM in an eventual anal surgery. In eight of the 50
patients with ARM, in the report of Thibault et al., ARM
was found incidentally during anal surgery (16.0%), and ﬁve
of them were reoperated, two with APR and three with
ELR, with no tumor trace in the surgical specimen at the
microscopy.
The ﬁndings of these authors are similar to ﬁndings in this
series of 14 ARMs: two were ARM cases incidentally found
during hemorrhoidectomy (14.2%). However, none of them
required reoperation, and both are alive – one 17 years after
surgery and the other 12 years after surgery. Therefore, it can
be concluded that these small tumors were cured with local
resection only.
Radiotherapy and chemotherapy are considered ineffec-
tive for treatment of ARM. Some authors who have used
RXT reported that they did not observe any advantage.3,24 In
this study, only one patient received chemotherapy and none
received RXT. The use of targeted therapies against metastatic
melanoma was considered frustrating by Satzger et al.11 How-
ever, knowledge of the different processes of oncogenesis of
melanomas can lead tomoreprecise therapies. Oneof the sub-
groups of ARM, with mutations in the BRAF gene, respond to
the action of BRAF inhibitors (PLX4032 and RAF265), leading to
regression of disease in up to 70% of patients with metastatic
melanoma with BRAF V600E mutation.25
Another subgroup of ARM, with KIT gene mutation, is sen-
sitive to c-KIT (imatinib) blocker action.25 Other blockers of
c-KIT have been studied in ARMs, however, in a very small
number of patients, which prevents drawing an immediate
conclusion.
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Conclusion
ARMs are tumors with high malignant potential, and their rar-
ity makes it difﬁcult to establish diagnostic and therapeutic
procedures with statistically signiﬁcant results. Histopatho-
logydoesnot always conﬁrm thediagnosis and IHC is essential
for attaining a deﬁnitive diagnosis.
The most rational surgical approach is the ELR in cases of
localized ARMs and APR for advanced cases of the disease.
Regardless of the surgical technique used, the overall survival
is very low.
There is no outcome improvement with CXR and CT. The
use of targeted therapies is starting to show encouraging
results for some subtypes (with mutations in BRAF and/or KIT
genes).
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